New Warnings Added to the Labeling for Kybella
Cases of injection site alopecia have been reported with the use of Kybella. The onset and duration may differ among patients and may persist. If this adverse reaction occurs, clinicians should consider withholding subsequent treatments until the reaction has resolved.
In addition, cases of ulceration and necrosis have been reported with the administration of Kybella following injections that are too superficial (into the dermis). Kybella should not be administered into the affected area until the reaction has completely resolved.
Kybella, a cytolytic agent, is approved to improve the appearance of moderate to severe convexity or fullness associated with submental fat in adult patients. The use of Kybella to treat subcutaneous fat outside the submental region has not been established and is not recommended.
Kybella is available in 2mL single-patient use vials in 4-count packs.
For more information call (800) 678-1605 or visit MyKybella.com.